Literature DB >> 218729

High incidence of mammary tumors in mice with inherited asplenia carriers for the nude gene.

B B Lozzio, D M Lopez, P Coulson, S V Lair.   

Abstract

A colony of mice suffering from dominant hemimelia associated with agenesis of the spleen has been developed and characterized during the past 7 years. The hereditarily asplenic (Dh/+) mice have a very low incidence (9%) of spontaneous mammary tumors (SMT). Asplenic (Dh/+) females were mated with mice homozygous (nu/nu) for hereditary athymia (nude) having a BALB/c background. BALB/c females heterozygous for the nu gene and with spleen (nu/+,+/+) have a moderate incidence (12%) of SMT, whereas nu/+,Dh/+ breeders have a drastic increase in the incidence of SMT to 46% when bred under identical conditions. Since all parent strains have a very low incidence of SMT, it appears that the spleen agenesis is a major factor accounting for an earlier and higher incidence of SMT in hereditarily asplenic (nu/+,Dh/+) mice than in normal (nu/+,+/+) siblings. The SMT express mammary tumor virus antigen(s) and possess estrogen, progesterone, and glucocorticoid receptors. The SMT rapidly metastasize and kill the host within 30 to 45 days. The BALB/c asplenic mice with SMT represent a unique model relevant to human breast cancer and for study of the function of the spleen in the development of solid tumors in general and of SMT in particular.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 218729

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Metastasizing mammary tumors. Spontaneous mammary tumors in asplenic mice heterozygous for athymia.

Authors:  J R Mitchell; B B Lozzio; E Machado; P Coulson; E Linton
Journal:  Am J Pathol       Date:  1982-11       Impact factor: 4.307

Review 2.  Immune Relevant and Immune Deficient Mice: Options and Opportunities in Translational Research.

Authors:  Enrico Radaelli; Sara F Santagostino; Rani S Sellers; Cory F Brayton
Journal:  ILAR J       Date:  2018-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.